New drug against Alzheimer’s disease – Health – Health

The drug, which will be sold under the Leqembi brand, belongs to a class of treatments that aim to slow the progression of neurodegenerative disease by eliminating the buildup of the toxic protein beta amyloid from the brain.

The Eisai lab said the annual cost of the drug administered by infusion would be around $26,500. The drug is intended for patients with dementia or mild cognitive impairment, a population that doctors say represents a small segment of those living with the memory-attacking disease. The trials showed that the new drug slowed the rate of cognitive decline in patients in the early stages of Alzheimer’s by 27%.

Short link:

Leave a Comment

Your email address will not be published. Required fields are marked *